Skip to main content

Dr. Benjamin L. Maughan, MD

Medical Oncology (Medical Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
16
In the NPI registry since
2010
Medicare patients seen, 2024
162

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2010Registered with an NPI (national billing number; not a license date)

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    TX license 49008
  • Hematology & Oncology Physician
    TX license 49008 · UT license 8134434-1205
  • Student in an Organized Health Care Education/Training Program

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
162
Services billed
662
Patients’ average age
75
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 40-54 minutes361136
Established patient office or other outpatient visit, 30-39 minutes10176

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 6 companies reported 31 payments worth $21,454 in total to this clinician.

By company
Bayer HealthCare Pharmaceuticals Inc.$11,584
Eisai Inc.$4,974
Pfizer Inc.$2,346
Eisai Co., LTD.$2,205
Exelixis Inc.$197
Aveo Pharmaceuticals, Inc.$148
By type
Consulting Fee$18,644
Food and Beverage$1,498
Travel and Lodging$1,312

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jul 25, 2025Bayer HealthCare Pharmaceuticals Inc.
Jul 25, 2025
Consulting Fee
Xofigo · Oncology
$7,210
Jul 26, 2025Bayer HealthCare Pharmaceuticals Inc.
Jul 26, 2025
Consulting Fee
Nubeqa · Oncology
$2,524
Dec 3, 2025Eisai Inc.
Dec 3, 2025
Consulting Fee
Lenvima · Oncology
$2,400
Mar 14, 2025Eisai Co., LTD.
Mar 14, 2025
Consulting Fee
Lenvima · Oncology
$2,205
Mar 14, 2025Eisai Inc.
Mar 14, 2025
Consulting Fee
Lenvima · Oncology
$2,205
Mar 12, 2025Pfizer Inc.
Mar 12, 2025
Consulting Fee
TALZENNA · ONCOLOGY
$2,100
Jul 25, 2025Bayer HealthCare Pharmaceuticals Inc.
Jul 25, 2025
Travel and Lodging
Xofigo · Oncology · travel to Rosemont, IL · in-kind
$576
Jul 24, 2025Bayer HealthCare Pharmaceuticals Inc.
Jul 24, 2025
Travel and Lodging
Xofigo · Oncology · travel to Rosemont, IL · in-kind
$238
Jul 25, 2025Bayer HealthCare Pharmaceuticals Inc.
Jul 25, 2025
Travel and Lodging
Xofigo · Oncology · travel to Rosemont, IL · in-kind
$238
Jul 24, 2025Bayer HealthCare Pharmaceuticals Inc.
Jul 24, 2025
Travel and Lodging
Xofigo · Oncology · travel to Rosemont, IL · in-kind
$215
All 12 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 3, 2025Eisai Inc.
Dec 3, 2025
Consulting Fee
Lenvima · Oncology
$2,400
Jul 26, 2025Bayer HealthCare Pharmaceuticals Inc.
Jul 26, 2025
Consulting Fee
Nubeqa · Oncology
$2,524
Jul 26, 2025Bayer HealthCare Pharmaceuticals Inc.
Jul 26, 2025
Travel and Lodging
Nubeqa · Oncology · travel to Rosemont, IL · in-kind
$26.88
Jul 25, 2025Bayer HealthCare Pharmaceuticals Inc.
Jul 25, 2025
Consulting Fee
Xofigo · Oncology
$7,210
Jul 25, 2025Bayer HealthCare Pharmaceuticals Inc.
Jul 25, 2025
Travel and Lodging
Xofigo · Oncology · travel to Rosemont, IL · in-kind
$576
Jul 25, 2025Bayer HealthCare Pharmaceuticals Inc.
Jul 25, 2025
Travel and Lodging
Xofigo · Oncology · travel to Rosemont, IL · in-kind
$238
Jul 24, 2025Bayer HealthCare Pharmaceuticals Inc.
Jul 24, 2025
Travel and Lodging
Xofigo · Oncology · travel to Rosemont, IL · in-kind
$238
Jul 24, 2025Bayer HealthCare Pharmaceuticals Inc.
Jul 24, 2025
Travel and Lodging
Xofigo · Oncology · travel to Rosemont, IL · in-kind
$215
Jul 24, 2025Bayer HealthCare Pharmaceuticals Inc.
Jul 24, 2025
Travel and Lodging
Nubeqa · Oncology · travel to Rosemont, IL · in-kind
$17.91
Mar 14, 2025Eisai Co., LTD.
Mar 14, 2025
Consulting Fee
Lenvima · Oncology
$2,205
Mar 14, 2025Eisai Inc.
Mar 14, 2025
Consulting Fee
Lenvima · Oncology
$2,205
Mar 12, 2025Pfizer Inc.
Mar 12, 2025
Consulting Fee
TALZENNA · ONCOLOGY
$2,100

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Texas →

Industry-funded research

Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $1,166,030 in research payments for these studies, mostly to the institutions running them.

  • An Open-Label Phase 2 Study to Evaluate PT2977 For The Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma
    Merck Sharp & Dohme LLC
  • A Multicenter, Open-label, Randomized, Phase 1,2 Study of Belzutifan in Combination with Palbociclib Versus Belzutifan Monotherapy in Participants with Advanced Renal Cell Carcinoma
    Merck Sharp & Dohme LLC
  • An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 …
    Merck Sharp & Dohme LLC
  • A Phase 2 Study of Radium-223 + Nivolumab in Men with Metastatic Castration Resistant Prostate Cancer
    E.r. Squibb & Sons, L.l.c.
  • BAY 1841788, A roll-over study to provide continued treatment with darolutamide in subjects who were entered in darolutamide studies
    Bayer HealthCare Pharmaceuticals Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in San Antonio

Sources

NPI registry (CMS NPPES, November 2026; record last updated March 12, 2026), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1255656120. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.